San Francisco, California, United States The leading representative office of defined Corporate Investor is situated in the San Francisco. The venture was found in North America in United States.
The usual cause for the fund is to invest in rounds with 5 partakers. Despite the BVF Partners, startups are often financed by Purdue Pharma, Versant Ventures, MPM Capital. The meaningful sponsors for the fund in investment in the same round are Versant Ventures, Wellington Management, Surveyor Capital.
Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Repare Therapeutics. For fund there is no match between the location of its establishment and the land of its numerous investments - Canada. Among the most successful fund investment fields, there are Health Care, Pharmaceutical.
The important activity for fund was in 2019. Deals in the range of 50 - 100 millions dollars are the general things for fund. The fund is generally included in 2-6 deals every year.
Related Funds
| Fund Name | Location |
| 1to4 Foundation | - |
| Aoou Wangluo Keji | China, Shanghai |
| AXON Connected | Earlysville, United States, Virginia |
| Barclays Investment Bank | Atlanta, Georgia, United States |
| Caspark | Beijing, China, Haidian |
| Christavest | - |
| Derbaix Ventures | Community of Madrid, Madrid, Spain |
| Gollust Management | - |
| Grupo Pegasus | - |
| GU Equity Partners | - |
| Hike | Delhi, India, New Delhi |
| Pamica | - |
| Pioneer | - |
| SPARK VCT | England, London, United Kingdom |
| Tennenbaum Capital Partners | California, Santa Monica, United States |
| Whales Capital | China, Shanghai |
| White Owl Capital Partners | New York, New York, United States |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Alpha9 Theranostics | $75M | 14 Dec 2022 | Vancouver, British Columbia, Canada | ||
Dren Bio | $65M | 14 Jun 2022 | California, United States | ||
Elektrofi | $40M | 13 Jun 2022 | Boston, Massachusetts, United States | ||
Ventus Therapeutics | $140M | 09 Feb 2022 | Massachusetts, United States | ||
Simcha Therapeutics | $40M | 27 Jan 2022 | New Haven, Connecticut, United States | ||
Third Harmonic Bio | $105M | 16 Jan 2022 | Cambridge, Massachusetts, United States | ||
AN2 Therapeutics | $80M | 07 Jan 2022 | California, United States | ||
Quanta Therapeutics | $60M | 26 Oct 2021 | San Francisco, California, United States | ||
Exo Therapeutics | $78M | 05 Oct 2021 | Cambridge, Massachusetts, United States |
– ShouTi Inc. announced the close of a $100m Series B financing round.
– The round was led by BVF Partners. Additional new investors include Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Lilly Asia Ventures, Monashee Capital, Sage Partners, Stork Capital, Surveyor Capital (a Citadel company), TCG X, Terra Magnum Capital Partners, Woodline Partners, and co-founder and strategic partner Schrödinger.
– Existing investors also participated in the financing, including Eight Roads, F-Prime Capital Partners, Qiming Venture Partners, Sequoia Capital China, TF Capital and Wuxi AppTec.
– HilleVax, Inc. (HilleVax), a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates, announced the close of a $135 million crossover financing led by Frazier Healthcare Partners and joined by RA Capital Management, Deerfield Management Company, Abingworth, Lightspeed Venture Partners, Perceptive Advisors, Catalys Pacific, Samsara BioCapital, BVF Partners, Qiming Venture Partners USA, Greenspring Associates, Richard King Mellon Foundation, and Sahsen Ventures.
– The proceeds of this financing support the further clinical development of HilleVax’s virus-like particle (VLP) based vaccine candidate, HIL-214, for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Alpha9 Theranostics | $75M | 14 Dec 2022 | Vancouver, British Columbia, Canada | ||
Dren Bio | $65M | 14 Jun 2022 | California, United States | ||
Elektrofi | $40M | 13 Jun 2022 | Boston, Massachusetts, United States | ||
Ventus Therapeutics | $140M | 09 Feb 2022 | Massachusetts, United States | ||
Simcha Therapeutics | $40M | 27 Jan 2022 | New Haven, Connecticut, United States | ||
Third Harmonic Bio | $105M | 16 Jan 2022 | Cambridge, Massachusetts, United States | ||
AN2 Therapeutics | $80M | 07 Jan 2022 | California, United States | ||
Quanta Therapeutics | $60M | 26 Oct 2021 | San Francisco, California, United States | ||
Exo Therapeutics | $78M | 05 Oct 2021 | Cambridge, Massachusetts, United States |
